Scientists from the University of Adelaide’s Research Centre for Infectious Diseases have developed a single vaccination approach to simultaneously combat influenza and pneumococcal infections, the world’s most deadly respiratory diseases.
The researchers say a single vaccination—combining vaccines from the new class of vaccines they are developing—will overcome the limitations of current influenza and pneumococcal vaccines used around the world.
Published today in the prestigious journal Nature Microbiology, they have shown that the new Influenza A virus vaccine under development (based on inactivated whole influenza virus) induces enhanced cross-protective immunity to different influenza strains, when it is co-administrated with the new class of pneumococcal vaccine.